| Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248) |
|---|
| 05/21/2013 | US8444982 Anti-IGF-IR antibodies and uses thereof |
| 05/21/2013 | US8444981 Alpha-4 beta-7 heterodimer specific antagonist antibody |
| 05/21/2013 | US8444980 Therapeutic use of anti-CS1 antibodies |
| 05/21/2013 | US8444979 Antibodies that inhibit TSLP activity |
| 05/21/2013 | US8444978 Angiogenic and immunologic applications of anti-CD160 specific compounds obtainable from mAb CL1-R2 |
| 05/21/2013 | US8444977 Assay method for Alzheimer's disease |
| 05/21/2013 | US8444975 Method for inhibiting bone resorption |
| 05/21/2013 | US8444974 Use of antibodies for the vaccination against cancer |
| 05/21/2013 | US8444973 Anti-CD19 antibodies and uses in B cell disorders |
| 05/21/2013 | US8444972 Antitumor antibodies, proteins, and uses thereof |
| 05/21/2013 | US8444971 OVR110 antibody compositions and methods of use |
| 05/21/2013 | US8444970 Compositions and methods for treating ocular diseases and conditions |
| 05/21/2013 | US8444965 Tumor cells from immune privileged sites as base cells for cell-based cancer vaccines |
| 05/21/2013 | US8444964 Compositions and methods for enhanced tumor cell immunity in vivo |
| 05/21/2013 | US8444957 Methods of screening for neoplastic disease states |
| 05/21/2013 | CA2707766C Plasmids ptqomp and ptto-1 which have an ompa signal sequence |
| 05/21/2013 | CA2553805C Improved inactivated feline calicivirus vaccines |
| 05/21/2013 | CA2522614C Vaccine accelerator factor (vaf) for improvement of vaccinations in poultry |
| 05/21/2013 | CA2477675C Immunizing composition and method for inducing an immune response against the .beta.-secretase cleavage site of amyloid precursor protein |
| 05/21/2013 | CA2460092C A method of diagnosis and treatment and agents useful for same |
| 05/21/2013 | CA2412436C Identification and use of human bone marrow-derived endothelial progenitor cells to improve myocardial function after ischemic injury |
| 05/21/2013 | CA2401638C Immuno-reactive peptide ctl epitopes of human cytomegalovirus |
| 05/21/2013 | CA2399080C Humanized anti-ccr2 antibodies and methods of use therefor |
| 05/21/2013 | CA2360146C Methods for inhibiting brain tumor growth by using selected integrin antagonists |
| 05/21/2013 | CA2305385C Human toll homologues |
| 05/21/2013 | CA2294865C Immunogenic lhrh compositions and methods relating thereto |
| 05/16/2013 | WO2013071298A1 Lactic acid bacteria and their use as dietary supplementals for poultry |
| 05/16/2013 | WO2013071068A2 Treatment of hematologic malignancies with an anti-cxcr4 antibody |
| 05/16/2013 | WO2013071058A1 Her3 antibodies and uses thereof |
| 05/16/2013 | WO2013071030A1 Provasopressin antagonists and uses thereof |
| 05/16/2013 | WO2013071016A2 Methods of inhibiting tumor growth by antagonizing il-6 receptor |
| 05/16/2013 | WO2013070879A1 Methods for treating spinal cord injury with lpa receptor antagonists |
| 05/16/2013 | WO2013070776A1 Neutralizing gp41 antibodies and their use |
| 05/16/2013 | WO2013070615A1 Combination therapies using anti- pseudomonas psl and pcrv binding molecules |
| 05/16/2013 | WO2013070565A1 Multispecific and multivalent binding proteins and uses thereof |
| 05/16/2013 | WO2013070468A1 Glypican-3-specific antibody and uses thereof |
| 05/16/2013 | WO2013070433A1 Targeting an amphiregulin-derived cell surface neo-epitope |
| 05/16/2013 | WO2013070048A1 Composition for preventing or treating ischaemic heart disease comprising, as an active ingredient, age-albumin synthesis or secretion inhibitor for mononuclear phagocyte system cells |
| 05/16/2013 | WO2013068949A1 Carrier molecule comprising a spr0096 and a spr2021 antigen |
| 05/16/2013 | WO2013068902A1 Methods of treating inflammatory disorders using anti-m-csf antibodies |
| 05/16/2013 | WO2013068847A2 Compositions and methods for treatment of cytomegalovirus |
| 05/16/2013 | WO2013068629A1 Live attenuated strain of actinobacillus pleuropneumoniae |
| 05/16/2013 | WO2013068593A1 Influenza virus -like particles (vlps) comprising hemagglutinin produced nicotiana tabacum |
| 05/16/2013 | WO2013068568A1 Fermentation media free of animal-derived components for production of diphtheria toxoids suitable for human vaccine use |
| 05/16/2013 | WO2013068563A2 Antibody molecules having specificity for human ox40 |
| 05/16/2013 | WO2013068431A1 New treatment for neurodegenerative diseases |
| 05/16/2013 | WO2013068406A1 Vaccine for tumor immunotherapy |
| 05/16/2013 | WO2013068399A1 Film packaging for oral biologics |
| 05/16/2013 | WO2013067873A1 Anti-influenza virus nucleic acid, peptide nucleic acid and formulation thereof |
| 05/16/2013 | WO2013067652A1 Facilitator-dna combination vaccine |
| 05/16/2013 | WO2013067639A1 Use of rank/rankl antagonists for treating neuromuscular disorders, genetic myopathies and/or non genetic myopathies and/or for regulating skeletal and cardiac muscle disuse, diseases and aging |
| 05/16/2013 | WO2013067581A1 Cancer treatment |
| 05/16/2013 | WO2013041877A3 Influenza virus mutant expressing a haemagglutinin protein without functional signal sequence for use as vaccine |
| 05/16/2013 | WO2013033400A9 Methods for effectively and rapidly desensitizing allergic patients |
| 05/16/2013 | WO2013014408A3 Vaccine |
| 05/16/2013 | WO2013001369A3 Therapeutic and diagnostic target |
| 05/16/2013 | WO2012136790A9 Compositions comprising fusion proteins or conjugates with an improved serum half-life |
| 05/16/2013 | WO2008058081A9 Feline vaccines against avian influenza |
| 05/16/2013 | US20130123477 Tiacumicin Production |
| 05/16/2013 | US20130123473 Bispecific antibody targeting a complement factor or complement regulatory protein |
| 05/16/2013 | US20130123122 Secreted proteins and uses thereof |
| 05/16/2013 | US20130122106 Dosage form, and methods of making and using the same, to produce immunization in animals and humans |
| 05/16/2013 | US20130122083 Dna vaccines encoding heat shock proteins |
| 05/16/2013 | US20130122080 Pharmaceutical composition capable of immuno-regulation or enhancement of immune response |
| 05/16/2013 | US20130122048 Tumor Cell-Based Cancer Immunotherapeutic Compositions and Methods |
| 05/16/2013 | US20130122047 Streptococcus pyogenes antigens |
| 05/16/2013 | US20130122045 Cross-Protective Influenza Vaccine |
| 05/16/2013 | US20130122044 Novel interferon-alpha-producing bone marrow dendritic cells |
| 05/16/2013 | US20130122041 Attenuated ehrlichiosis vaccine |
| 05/16/2013 | US20130122039 V. Cholera hypereexpressing recombinant cholera toxin B subunit showing dual immunogenicity |
| 05/16/2013 | US20130122037 Vault Compositions for Immunization |
| 05/16/2013 | US20130122033 Fimh vaccine against urinary tract infections (uti) |
| 05/16/2013 | US20130122032 Recombinant nanoparticle rsv f vaccine for respiratory syncytial virus |
| 05/16/2013 | US20130122030 S. epidermidis antigens |
| 05/16/2013 | US20130122029 Cancer vaccine |
| 05/16/2013 | US20130122026 Dna vaccine for alzheimer's disease |
| 05/16/2013 | US20130122025 Method of rapidly producing improved vaccines for animals |
| 05/16/2013 | US20130122024 New binder-drug conjugates (adcs) and use thereof |
| 05/16/2013 | US20130122021 B7-h3 in cancer |
| 05/16/2013 | US20130122018 HUMAN ANTIBODIES THAT BIND HUMAN TNFalpha |
| 05/16/2013 | US20130122017 Osteoprotegerin in Neuroprotection |
| 05/16/2013 | US20130122013 Anti-ferroportin 1 monoclonal antibodies and uses thereof |
| 05/16/2013 | US20130122011 Multiple-variable dose regimen for treating TNFa-related disorders |
| 05/16/2013 | US20130122008 Anti-IL 1- ß Antibody Combination Therapy |
| 05/16/2013 | US20130122007 Compositions and Methods for Increasing Muscle Mass and Muscle Strength by Specifically Antagonizing GDF8 and or Activin A |
| 05/16/2013 | US20130122005 Anticancer combination therapy |
| 05/16/2013 | US20130122003 Methods of inhibiting tumor growth by antagonizing il-6 receptor |
| 05/16/2013 | US20130121999 Blood plasma biomarkers for bevacizumab combination therapies for treatment of breast cancer |
| 05/16/2013 | US20130121997 Binding agents |
| 05/16/2013 | US20130121996 Novel Complex Mutations in the Epidermal Growth Factor Receptor Kinase Domain |
| 05/16/2013 | US20130121995 Compositions and Methods for Increasing Bone Mineralization |
| 05/16/2013 | US20130121994 Triazolopyridine derivatives |
| 05/16/2013 | US20130121993 Compositions and Methods for Treating and Diagnosing Cancer |
| 05/16/2013 | US20130121991 Concentrated human immunoglobulin composition |
| 05/16/2013 | US20130121988 Nucleic Acid of Formula (I): GlXmGn, or (II): ClXmCn, in Particular as an Immune-Stimulating Agent/Adjuvant |
| 05/16/2013 | US20130121964 Pharmacogenomic and Response-Guided Treatment of Infectious Disease Using Yeast-Based Immunotherapy |
| 05/16/2013 | US20130121960 Constitutive expression of costimulatory ligands on adoptively transferred t lymphocytes |
| 05/16/2013 | US20130121959 Il-22-fc and hepcidin activity |
| 05/16/2013 | US20130121958 Streptavidin and biotin-based antigen delivery system |
| 05/16/2013 | US20130121914 Treatment drug for autoimmune diseases and allergic diseases |